BNTX Congressional Stock Trades
BioNTech SE - American Depositary Shares (BNTX)
Last disclosed trade Sep 3
Every disclosed trade in BNTX by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.
Sample · the intelligence layer
Josh Gottheimer · Sold $BNTX · Aug 30 · $1K–$15K
Managed-account penalty applied (x 0.20): filings dominated by trust or wealth-manager activity are discounted.
Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →
Follow $BNTX
Get notified when any member of Congress trades $BNTX. Free, no card, no spam.
The record on $BNTX
Coldpine has parsed 7 disclosed trades in $BNTX by 1 member of Congress, drawn from 5 periodic transaction reports dated Dec 5, 2023 through Sep 3, 2024. All of them came from House members, all filed by Democrats.
Of the 7 trades with a known filing lag, every one was reported inside the STOCK Act's 45-day window. The median lag was 30 days. The longest was 33 days: a $BNTX purchase by Josh Gottheimer dated Dec 5, 2023, disclosed Jan 7, 2024. How late filing is measured across all of Congress is in the late-filers study.
7 of the 7 trades that list an account holder (100%) were reported under a spouse, dependent child, or joint account rather than the member directly.
Activity peaked in 2024 with 4 trades.
Members who trade BNTX
Recent disclosed trades in BNTX
| Date | Member | Type | Amount |
|---|---|---|---|
| Sep 3 | Josh Gottheimer(NJ) | sell | $1K–$15K |
| Aug 30 | Josh Gottheimer(NJ) | sell | $1K–$15K |
| Apr 15 | Josh Gottheimer(NJ) | buy | $1K–$15K |
| Mar 14 | Josh Gottheimer(NJ) | sell | $1K–$15K |
| Dec 7 | Josh Gottheimer(NJ) | buy | $1K–$15K |
| Dec 6 | Josh Gottheimer(NJ) | buy | $1K–$15K |
| Dec 5 | Josh Gottheimer(NJ) | buy | $1K–$15K |
Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →